TREAT-NMD TACT Review
Debra Miller, founder and CEO of CureDuchenne; Kate Busby, TREAT-NMD project coordinator; and Dr. Michael Kelly, chief scientific officer at CureDuchenne, during the TREAT-NMD TACT Review meeting in Washington, DC on April 28 and April 29.
CureDuchenne was honored to participate in the TREAT-NMD TACT review for Duchenne research held on April 28 and 29 in Washington, DC. TREAT-NMD (http://www.treat-nmd.eu/) is a European-based network for the neuromuscular field that is focused on creating infrastructure, scientific review and guidance to ensure that the most promising new therapies reach patients as quickly as possible. It was an international cooperative meeting thanks to Kate Busby, TREAT-NMD Project Coordinator, Professor of Neuromuscular Genetics - Newcastle University, and her wonderful team, including Cristina Csimma, and many other world renowned scientists, clinicians and statisticians. CureDuchenne and PPMD co-sponsored the meeting.
Debra Miller, founder and CEO of CureDuchenne, and Michael Kelly, Ph.D., Chief Scientific Officer of CureDuchenne, participated in the review. Dr. Kelly was able to offer his 25 years of drug development experience to the review committee.
Of the many promising research results presented at conferences, published in journals and hailed as the basis for possible future treatments and cures, only a handful progress into clinical trial. Evaluating the therapeutic potential of drugs seemingly ready for this step is a challenge not only for the patients who build hope on preclinical results and for the potential funders and industry sponsors of the research, but also for the researchers themselves. In this context, the TREAT-NMD TACT review process is a critical component of identifying, prioritizing and helping the most promising projects. Read more information on TACT.